Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/2977
|
| Title: | Nodal dissection for patients with gastric cancer: a randomised controlled trial |
| Authors: | Wu, CW;Hsiung, CA;Lo, SS;Hsieh, MC;Chen, JH;Li, AFY;Lui, WY;Whang-Peng, J |
| Contributors: | National Institute of Cancer Research;Division of Biostatistics and Bioinformatics |
| Abstract: | Background The survival benefit and morbidity after nodal dissection for gastric cancer remains controversial. We aimed to do a single-institution randomised trial to compare D1 (ie, level 1) lymphadenectomy with that of D3 (ie, levels 1, 2, and 3) dissection for gastric cancer in terms of overall survival and disease-free survival. Methods From Oct 7, 1993, to Aug 12, 1999, 335 patients were registered. 221 patients were eligible, 110 of whom were randomly assigned D1 surgery and ill of whom were randomly assigned D3 surgery, both with curative intent. Three participating surgeons had done at least 25 independent D3 dissections before the start of the trial, and every procedure was verified by pathological analyses. The primary endpoints were 5-year overall survival and 5-year disease-free survival. We also analysed risk of recurrence. Main analyses were done by intention to treat. This trial is registered at the US National Institute of Health website http://www.clinicaltrials.gov/ct/show/NCT00260884. Findings Median follow-up for the 110 (50%) survivors was 94.5 months (range 62.9-135.1). Overall 5-year survival was significantly higher in patients assigned D3 surgery than in those assigned D1 surgery (59.5% [95% CI 50.3-68.7] vs 53.6% [44.2-63.0]; difference between groups 5.9% [-7.3 to 19.1], log-rank p = 0.04). 215 patients who had R0 resection (ie, no microscopic evidence of residual disease) had recurrence at 5 years of 50.6% [41.1-60.2] for D1 surgery and 40.3% [30.9-49.7] for D3 surgery (difference between groups 10.3% [-3.2 to 23,7], log-rank p = 0.197). Interpretation D3 nodal dissection, compared with that of D1, offers a survival benefit for patients with gastric cancer when done by well trained, experienced surgeons. |
| Keywords: | Oncology |
| Date: | 2006-04 |
| Relation: | Lancet Oncology. 2006 Apr;7(4):309-315. |
| Link to: | http://dx.doi.org/10.1016/S1470-2045(06)70623-4 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1470-2045&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000236873200028 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33645774635 |
| Appears in Collections: | [彭汪嘉康(1996-2007)] 期刊論文
[熊昭] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 000236873200028.pdf | | 120Kb | Adobe PDF | 885 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
